Perspective Therapeutics (CATX) Income from Continuing Operations (2010 - 2026)

Perspective Therapeutics has disclosed Income from Continuing Operations across 17 years of filings, most recently posting -$27.0 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations fell 22.66% year-over-year to -$27.0 million; the TTM figure through Jun 2026 stood at -$120.0 million (down 21.77% YoY), while the FY2025 annual figure was -$104.4 million, down 28.33% from the prior year.
• Income from Continuing Operations came in at -$27.0 million for Q2 2026 at Perspective Therapeutics, up from -$28.7 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of -$371000.0 in Q1 2023 to a low of -$43.2 million in Q4 2024.
• Average Income from Continuing Operations over 5 years is -$16.7 million, with a median of -$13.5 million recorded in 2024.
• Year-over-year, Income from Continuing Operations surged 72.46% in 2023 and slumped 3087.33% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$6.3 million in 2022, then tumbled by 187.44% to -$18.0 million in 2023, then plunged by 139.71% to -$43.2 million in 2024, then grew by 11.41% to -$38.3 million in 2025, then gained by 29.52% to -$27.0 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$27.0 million in Q2 2026, -$28.7 million in Q1 2026, and -$38.3 million in Q4 2025.